Canada Clears Antibiotic Combo Of India’s Orchid
This article was originally published in PharmAsia News
India's Orchid Chemicals and Pharmaceuticals got Canadian clearance to sell its combination piperacillin-tazobactam antibiotic. The Therapeutic Products Directorate allowed the combination of antibiotic injections for treating bacterial infections. Piperacilin is based on penicillin and tazobactam enhances its effectiveness. (Click here for more
You may also be interested in...
MUMBAI - U.S. drug maker Wyeth will see its first competition in Europe for key antibiotic drug Zosyn, or Tazocin, from Indian drug maker Orchid Chemicals. After almost a wait of more than a year, Orchid received approvals or Marketing Authorization for piperacillin/tazobactum injectibles in the EU countries
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
MUMBAI - India's Patent Office in New Delhi on June 19 discarded a patent application for a pediatric version of German drug maker Boehringer Ingelheim's antiretroviral drug Viramune (nevirapine)